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Abstract
Background: Mesenchymal stem cells (MSCs) stabilise endothelial barrier function in acute lung injury via paracrine
hepatocyte growth factor (HGF). Vascular endothelial growth factor (VEGF), which is secreted by MSCs, is another key
regulator of endothelial permeability; however, its role in adjusting permeability remains controversial. In addition,
whether an interaction occurs between HGF and VEGF, which are secreted by MSCs, is not completely understood.
Methods: We introduced a co-cultured model of human pulmonary microvascular endothelial cells (HPMECs) and
MSC conditioned medium (CM) collected from MSCs after 24 h of hypoxic culture. The presence of VEGF and HGF in
the MSC-CM was neutralised by anti-VEGF and anti-HGF antibodies, respectively. To determine the roles and mechanisms
of MSC-secreted HGF and VEGF, we employed recombinant humanised HGF and recombinant humanised VEGF
to co-culture with HPMECs. Additionally, we employed the RhoA inhibitor C3 transferase and the Rac1 inhibitor
NSC23766 to inhibit the activities of RhoA and Rac1 in HPMECs treated with MSC-CM or VEGF/HGF with the same
dosage as in the MSC-CM. Then, endothelial paracellular and transcellular permeability was detected. VE-cadherin,
occludin and caveolin-1 protein expression in HPMECs was measured by western blot. Adherens junction proteins,
including F-actin and VE-cadherin, were detected by immunofluorescence.
Results: MSC-CM treatment significantly decreased lipopolysaccharide-induced endothelial paracellular and transcellular
permeability, which was significantly inhibited by pretreatment with HGF antibody or with both VEGF and HGF
antibodies. Furthermore, MSC-CM treatment increased the expression of the endothelial intercellular adherence
junction proteins VE-cadherin and occludin and decreased the expression of caveolin-1 protein. MSC-CM treatment also
decreased endothelial apoptosis and induced endothelial cell proliferation; however, the effects of MSC-CM treatment
were inhibited by pretreatment with HGF antibody or with both HGF and VEGF antibodies. Additionally, the effects of
MSC-CM and VEGF/HGF on reducing endothelial paracellular and transcellular permeability were weakened when
HPMECs were pretreated with the Rac1 inhibitor NSC23766.
Conclusion: HGF secreted by MSCs protects the endothelial barrier function; however, VEGF secreted by MSCs
may synergize with HGF to stabilise endothelial cell barrier function. Rac1 is the pathway by which MSC-secreted
VEGF and HGF regulate endothelial permeability.
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Background
Acute lung injury (ALI) is characterised by increased lung
permeability, pulmonary oedema and diffuse inflammation
and is involved in the disruption of alveolar–capillary
membranes [1]. Many agents, such as bacterial lipopoly-
saccharide (LPS), lead to an increase in permeability by
activating the inflammatory response, which contributes
to the development of ALI [2]. Because endothelial cells
(ECs) play a major role in ALI by changing their barrier
permeability, pulmonary EC dysfunction is a key compo-
nent of ALI pathogenesis. Thus, stabilising EC barrier
function is critical for treating ALI.
Our previous study provided convincing data regard-
ing the beneficial effects of mesenchymal stem cells
(MSCs) in treating endotoxin-induced ALI [3]. MSCs
have potent effects on alleviating vascular endothelium
injury by inhibiting endothelial permeability after injury
via the modulation of adherens junction (AJ) proteins
[4]. However, the detailed pathogenesis of MSCs in
reducing endothelial permeability remains unclear. Stud-
ies have shown that the multipotent differentiation of
MSCs contributes minimally to their beneficial effects,
while paracrine activity may play a predominant role in
MSC function [5, 6]. Thus, MSCs improve endothelial
injury primarily through a paracrine mechanism.
MSC-secreted hepatocyte growth factor (HGF) and
vascular endothelial growth factor (VEGF) are two im-
portant factors associated with endothelial permeability
[7]. HGF is present in the lung circulation under patho-
logical conditions such as ALI and exhibits sustained
barrier protective effects on human pulmonary ECs [8].
VEGF increases paracellular endothelial permeability, in
contrast to HGF, but decreases EC apoptosis and im-
proves cell viability [9]. Furthermore, VEGF reduces the
transcellular permeability of ECs upon LPS stimulation
[10]. Different quantities and proportions of HGF and
VEGF may exhibit different effects on endothelial per-
meability. Therefore, determining the detailed roles of
MSC-secreted HGF and VEGF in regulating endothelial
permeability is necessary. An LPS-induced increase in
endothelial permeability is regulated by Rho GTPases.
Rac1 is required for the maintenance of intercellular
adherens and tight junctions; however, RhoA contributes
to the breakage of intercellular adherens and tight junc-
tions [11]. The role of Rho GTPases in HGF and VEGF
regulation of endothelial permeability is also not fully
understood.
The aim of the present study was to determine the
effects and mechanisms of MSC-secreted HGF and VEGF
on LPS-induced endothelial permeability. We investigated
the effects of MSC-secreted HGF and VEGF on endothe-
lial paracellular and transcellular permeability in in vitro
co-culture experiments by neutralising HGF or VEGF
with HGF or VEGF antibody and then explored the
mechanisms by which MSC-secreted HGF and VEGF
regulate endothelial permeability by inhibiting RhoA and
Rac1 activities with RhoA and Rac1 inhibitors.
Materials and methods
Cell culture
Human mesenchymal stem cells (hMSCs) were purchased
from Cyagen Biosciences, Inc. (Guangzhou, China). Hu-
man pulmonary microvascular endothelial cells (HPMECs)
were obtained from ScienCell Research Laboratories.
hMSCs were cultured in MSC growth medium (Cyagen
Biosciences, Inc.), and HPMECs were cultured in endothe-
lial growth medium (EGM-2; ScienCell Research Labora-
tories, USA). The cells were cultured in a humidified 5 %
CO2 incubator at 37 °C. The culture media were changed
every 2–3 days, and the cells at passages 3–7 were used for
all experiments.
Hypoxia culture
For hypoxia treatment, hMSCs were cultured for 3 days
until confluent. A serum-free culture (supplemented with
0.05 % bovine serum albumin (BSA)) was used before
hypoxic culture. hMSCs (1,000,000 cells per culture flask)
were placed in a hypoxia incubator (BioSpherix, USA) for
24 h in an atmosphere of N2 (94.5 %), O2 (0.5 %) and CO2
(5 %). After 24 h of hypoxic culture, supernatants were
collected and centrifuged to remove debris.
Enzyme-linked immunosorbent assay
After 24 h of hypoxic culture, supernatants were
collected and centrifuged to remove debris. VEGF and
HGF were determined via an enzyme-linked immuno-
sorbent assay (ELISA) using commercially available
ELISA sets (ExCell Biology, Inc., Shanghai, China). We
further tested VEGF and HGF concentration by ELISA
quantification after adding anti-VEGF and anti-HGF
antibody on MSC conditioned medium (CM) using
1 ng/ml, 10 ng/ml, 100 ng/ml, and 1000 ng/ml, respectively.
ELISA was performed according to the manufacturer’s
instructions. All samples were measured in duplicate. We
have assessed the blocking effect of anti-HGF and anti-
VEGF antibody on MSC-CM. The result showed the actual
levels of HGF and VEGF were 343 pg/ml and 99 pg/ml,
respectively, in MSC-CM after 24 h of hypoxic culture.
However, VEGF in MSC-CM was significantly blocked by
10 ng/ml or more anti-VEGF antibody (p < 0.01), while
100 ng/ml or more anti-HGF antibody significantly blocked
HGF in MSC-CM (p < 0.01) (Fig. 1).
Co-culture protocol
HPMECs were cultured at a density of 50,000 cells per well
in six-well culture plates. After the HPMECs reached con-
fluence, the medium was changed with fresh culture
medium or hMSC hypoxia culture supernatants that
Yang et al. Stem Cell Research & Therapy  (2015) 6:250 Page 2 of 14
contained anti-HGF antibody (100 ng/ml; Abcam, Hong
Kong), anti-VEGF antibody (10 ng/ml; Abcam, Hong
Kong), or both anti-HGF (100 ng/ml) and anti-VEGF anti-
bodies (10 ng/ml). After the HPMECs were cultured for
24 h, HPMEC monolayers were treated with 100 ng/ml
LPS (Sigma, USA). To determine the roles and mechanisms
of MSC-secreted HGF and VEGF, we employed HPMECs
with LPS stimulation to co-culture with recombinant
humanised HGF (343 pg/ml; PEPROPECH, USA) and re-
combinant humanised VEGF (99 pg/ml; PEPROPECH,
USA) with the same dosage as in the MSC-CM. Further-
more, the RhoA inhibitor C3 transferase (5 μg/ml; Cyto-
skeleton, USA) and the Rac1 inhibitor NSC23766 (50 μM;
TOCRIS, USA) were used to inhibit the activities of RhoA
and Rac1 in HPMECs treated with MSC-CM or recombin-
ant VEGF/HGF (99 pg/ml and 343 pg/ml, respectively).
HPMEC permeability examination
HPMECs were seeded at 50,000 cells per insert well
(0.4 μm pore size polyester membrane from Corning,
Inc., USA) and cultured for 1 to 3 days to allow the
growth of a confluent monolayer. After different groups
received different treatments, HPMEC monolayers were
treated with 100 ng/ml LPS for 6 h before testing perme-
ability. Paracellular and transcellular permeability was
tested as described previously [12]. In brief, paracellular
permeability was tested by adding 10 μl of 10 mg/ml fluor-
escein isothiocyanate (FITC)-Dextran (Sigma-Aldrich) to
the upper chamber. The FITC-Dextran component from
samples was obtained 40 min after the addition of FITC-
Dextran. Medium (100 μl) was withdrawn from the lower
well and the upper well, respectively. Then measurements
were taken with a microplate reader using excitation and
emission wavelengths of 490 and 525 nm, respectively.
Paracellular permeability was calculated as previously de-
scribed [12]. To test transcellular permeability, 10 μl of
0.4 mg/ml FITC-BSA (Invitrogen, USA) was added to the
upper chamber. The remaining experimental procedure of
transcellular permeability detection is the same as that of
paracelluar permeability.
Western blot analysis
After treatment, total protein from HPMECs was extracted
using RIPA lysis buffer supplemented with 1 mmol/l phe-
nylmethanesulfonyl fluoride (Beyotime Institute of Biotech-
nology), followed by separation by 6 or 12 % SDS-PAGE
and transfer onto polyvinylidene fluoride membranes
(Nanjing, China). Then the membranes were blocked in
phosphate-buffered saline-Tween (PBS-T) containing
5 % milk for 2 h at room temperature and incubated at
4 °C overnight with primary antibodies against VE-
cadherin (1:1000; Cell Signaling), occludin (1:250;
Abcam) or caveolin-1 (1:1000; Epitomics). The next
day, the membranes were washed in PBS-T and incu-
bated in peroxidase-conjugated secondary antibody
(1:1000; HuaAn Biotechnology, Hangzhou, China) for
1 h at room temperature. Signals from immunoreactive
bands were visualised using a chemiluminescence im-
aging system (ChemiQ 4800 mini, Ouxiang, Shanghai,
China) after incubation with a horseradish peroxidase.
Immunofluorescence
In total, 5 × 104 HPMECs were seeded in six-well culture
plates and cultured for 1 to 3 days to allow for the
growth of a confluent monolayer. After treatment,
HPMEC monolayers were treated with 100 ng/ml LPS
before immunofluorescence analysis. After the HPMECs
were treated for 6 h, they were washed in cold PBS and
fixed in 4 % paraformaldehyde. Then the cells were
incubated with 1 % BSA in PBS for 30 min to block
non-specific binding and incubated with VE-cadherin anti-
body (1:50; Cell Signaling) or F-actin antibody (5 μg/ml;
Fig. 1 The blocking effect of a anti-VEGF and b anti-HGF antibody on VEGF and HGF in MSC-CM. The results showed the actual levels of HGF and VEGF
were 343 pg/ml and 99 pg/ml, respectively, in MSC-CM after 24 h of hypoxic culture. However, VEGF in MSC-CM was significantly blocked by 10 ng/ml
or more anti-VEGF antibody (p < 0.01), while 100 ng/ml or more anti-HGF antibody significantly blocked HGF in MSC-CM (p < 0.01); n = 3, *p < 0.01 vs.
0 ng/ml. CM Conditioned medium, HGF Hepatocyte growth factor, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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Abcam) at 4 °C overnight. Next, the cells were incubated
with FITC-conjugated goat anti-mouse IgG (1:200;
Jackson). Finally, DAPI (1:100; 4,6-diamidino-2-pheny-
lindole) was used to stain nuclei. Single plain images of
cells were obtained by fluorescence microscopy (Olympus).
Pull-down assays
HPMECs were cultured in six-well culture plates until
reaching confluence and then incubated overnight in
medium supplemented with 1 % serum before treatment.
RhoA activity was measured using a recombinant GST-Rho
binding domain bound to glutathione beads (Thermo Sci-
entific), and Rac1 activity was measured using GST-human
Pak1-PBD (Thermo Scientific). Affinity-precipitated RhoA
and Rac1 proteins were separated by SDS-PAGE and
detected by western blot. The detailed protocols for RhoA
and Rac1 pull-downs were provided by Thermo Scientific
(RhoA and Rac1 activation assay kits).
Viability and apoptosis assays
The viability of HPMECs was evaluated by 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium (MTT; Sigma) assay.
HPMECs were cultured in 24-well culture plates until
reaching 75–85 % confluence. After the cells were treated,
60 μl MTT (5 mg/ml) was added to each well and incu-
bated at 37 °C for 4 h. Then 200 μl dimethyl sulfoxide
(DMSO; Sigma) was added to the wells and incubated for
15 min. Finally, HPMEC viability was assessed by measur-
ing the absorbances of the sample at 570 nm and 630 nm.
HPMEC apoptosis was assessed using an annexin V-
FITC assay kit (Sigma) according to the manufacturer’s
instructions. After treatment, HPMECs were harvested
and washed in PBS. HPMECs were suspended in PBS at
a concentration of 1 × 106 cells/ml and then incubated
with 5 μl annexin V-FITC conjugate (annexin V) and
10 μl propidium iodide solution, followed by analysis
using a flow cytometer (BD Biosciences).
Statistical analyses
Statistical analyses were performed using the SPSS 16.0
software package. The data were presented as the mean ±
standard deviation. For group comparisons, one-way ana-
lysis of variance was used, followed by Tukey’s multiple
comparison tests. p values less than 0.05 were considered
statistically significant.
Results
MSC-secreted HGF and VEGF have a synergistic effect on
reducing HPMEC permeability
To evaluate the effects of MSC-secreted HGF and VEGF
on HPMEC permeability, we introduced a co-cultured
model using HPMECs and MSC-CM collected from
MSCs after 24 h hypoxia culture. VEGF and HGF in the
MSC-CM were neutralised with anti-VEGF and HGF
antibodies, respectively, followed by the detection of
endothelial paracellular and transcellular permeability.
The results showed that MSC-CM treatment reduced
LPS-induced endothelial paracellular permeability; how-
ever, the MSC-CM effect was significantly blocked by
anti-HGF antibody (p < 0.05 and p < 0.01; Fig. 2a). Mean-
while, MSC-CM treatment reduced LPS-induced transcel-
lular permeability, and the effect of MSC-CM treatment
was significantly blocked by anti-HGF antibody or anti-
VEGF antibody. Furthermore, the role of MSCs in
Fig. 2 MSCs reduced HPMEC permeability by secreting paracrine VEGF and HGF. The result showed that MSC-CM treatment reduced LPS-induced
endothelial paracellular permeability; however, the effect of MSC-CM treatment was significantly blocked by anti-HGF antibody (p < 0.05 and p < 0.01;
a). Meanwhile, MSC-CM treatment reduced LPS-induced transcellular permeability (b), and the effect of MSC-CM treatment was significantly blocked
by anti-HGF antibody or anti-VEGF antibody. Furthermore, the role of MSCs in reducing transcellular permeability was clearly inhibited by anti-HGF and
anti-VEGF antibodies. Adding MSC-CM in all groups except control group and LPS group. n = 3, *p < 0.01 vs control group; #p < 0.01 vs LPS group; &p
< 0.05; $p < 0.01 vs MSC-CM group. CM Conditioned medium, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell,
VEGF Vascular endothelial growth factor
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reducing transcellular permeability was clearly inhibited
by anti-HGF and anti-VEGF antibodies (p < 0.05; Fig. 2b).
The results suggested that MSCs lessen endothelial para-
cellular permeability by secreting paracrine HGF and re-
duce transcellular permeability by secreting paracrine
VEGF and HGF.
The combined effects of MSC-secreted HGF and VEGF on
endothelial adhesive junction upregulation and caveolin-1
protein expression downregulation
To illustrate the effects of MSC-secreted HGF and
VEGF on endothelial permeability-associated proteins,
we examined endothelial VE-cadherin, occludin and
caveolin-1 protein expression under co-culture condi-
tions. The results showed that LPS stimulation of
HPMECs reduced the expression of VE-cadherin and
occludin proteins (p < 0.01; Fig. 3b and c) and increased
the expression of caveolin-1 protein (p < 0.05; Fig. 3d)
and that these effects were inhibited by MSC. However,
the effect of MSCs was significantly blocked by anti-
HGF antibody (p < 0.05; Fig. 3). Furthermore, the role of
MSCs in reducing caveolin-1 protein expression was
clearly inhibited by anti-HGF and anti-VEGF antibodies.
The results indicated that MSC-secreted HGF upregulated
endothelial VE-cadherin and occludin protein expression
and downregulated caveolin-1 protein expression.
MSC-secreted HGF restored endothelial VE-cadherin and
F-actin remodelling
We further investigated the role of MSC-secreted para-
crine VEGF and HGF in regulating the remodelling of
the endothelial actin cytoskeleton and intercellular AJs.
LPS causes the remodelling of the junctional localisation
of VE-cadherin, which causes HPMEC to contract,
increasing paracellular permeability. After 24 h of MSC-
CM and HPMEC co-culture, the remodelling of the junc-
tional localisation of VE-cadherin was partially restored.
However, neutralising HGF from the MSC-CM with anti-
HGF antibody caused VE-cadherin to be disrupted again
(Fig. 4). Furthermore LPS causes “actin stress fibre”
Fig. 3 MSC-secreted paracrine HGF upregulated endothelial VE-cadherin protein expression and decreased caveolin-1 protein expression. The results
showed that LPS stimulation of HPMECs reduced the expression of VE-cadherin and occludin protein (p < 0.01; a, b, c) but increased the expression of
caveolin-1 protein (p < 0.05; a, d) and that these effects were inhibited by MSCs. However, the effect of MSCs was significantly blocked by anti-HGF
antibody (p < 0.05). Furthermore, the role of MSCs in reducing caveolin-1 protein expression was clearly inhibited by anti-HGF and anti-VEGF antibodies.
Adding MSC-CM in all groups except control group and LPS group. n = 3, *p < 0.05, **p < 0.01 vs. control group; #p < 0.05 vs. LPS group; &p < 0.05 vs.
MSC-CM group. CM Conditioned medium, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endo-
thelial growth factor
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formation in HPMEC, which is the movement of actin
from the cortical rim to a disorganized intracellular fash-
ion. It is this stress fibre formation which causes the cells
to contract, increasing paracellular permeability. After
24 h of MSC-CM and HPMEC co-culture, actin stress
fibre was partially restored. However, neutralising HGF
from the MSC-CM with anti-HGF antibody caused actin
stress fibre formation again (Fig.5).
MSC-secreted VEGF and HGF decreased HPMEC apoptosis
and improved cell viability
HPMEC survival was evaluated by apoptosis and cell
viability assays. The effect of MSCs on HPMEC apop-
tosis was assessed using an annexin V-FITC assay kit.
The results showed that LPS induced early apoptosis of
HPMECs. MSC-CM treatment significantly reduced the
number of early apoptotic cells (p < 0.05; Fig. 6a and b).
However, the effect of MSCs was significantly blocked
by neutralising HGF or VEGF from the MSC-CM with
anti-HGF or anti-VEGF antibody, respectively (p < 0.05
and p < 0.01, respectively; Fig. 6a and b). The cell viabil-
ity results of the MTT assay confirmed that MSC-CM
restored cell viability to a greater extent than did LPS
stimulation only (p < 0.05; Fig. 6c). Additionally, the
effect of MSC-CM treatment was significantly inhibited
by neutralising VEGF from the MSC-CM with anti-
VEGF antibody (p < 0.05; Fig. 6c).
MSC-secreted VEGF and HGF upregulated Rac1 activity
and downregulated RhoA activity in LPS-stimulated
HPMECs
To explore the mechanisms by which MSC-secreted
HGF and VEGF improved HPMEC permeability, we
investigated the effects of MSC-secreted HGF and VEGF
on Rac1 and RhoA activities in LPS-stimulated HPMECs.
Our results showed that MSC-CM treatment upregulated
Rac1 activity and downregulated RhoA activity in LPS-
stimulated HPMECs. However, the effect of MSCs was
significantly inhibited by neutralising HGF or both VEGF
and HGF from the MSC-CM with HGF antibody or both
VEGF and HGF antibodies (p < 0.05 and p < 0.01, respect-
ively; Fig. 7). Neutralising VEGF from the MSC-CM with
anti-VEGF did not affect the effect of MSCs. These result
suggested that MSC-secreted HGF upregulated Rac1 ac-
tivity and downregulated RhoA activity in LPS-stimulated
HPMECs.
RhoA and Rac1 activities in LPS-stimulated HPMECs were
inhibited by RhoA and Rac1 inhibitors, respectively
The above research suggested that the mechanism by
which MSC-secreted VEGF and HGF reduced HPMEC
Fig. 4 MSC-secreted HGF restored endothelial VE-cadherin remodelling. LPS causes the remodelling of the junctional localisation of VE-cadherin, which
causes HPMEC to contract, increasing paracellular permeability. After 24 h of MSC-CM and HPMEC co-culture, the remodelling of the junctional localisation
of VE-cadherin was partially restored. However, neutralising HGF from the MSC-CM with anti-HGF antibody caused VE-cadherin to be disrupted again.
Adding MSC-CM in all groups except control group and LPS group. CM Conditioned medium, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC
Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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permeability might function via regulating RhoA and
Rac1 activities. To confirm this hypothesis, we employed
the RhoA inhibitor C3 transferase and the Rac1 inhibitor
NSC23766 to inhibit RhoA and Rac1 activities, respect-
ively, in HPMECs treated with MSCs or VEGF/HGF.
Furthermore, we adopted human recombinant VEGF
and HGF with the same dosage as in the MSC-CM to
culture HPMECs. The results showed that C3 transfer-
ase significantly inhibited RhoA activity and that
NSC23766 inhibited Rac1 activity in injured HPMECs
treated with MSCs or VEGF/HGF (p < 0.05 and p < 0.01,
respectively; Fig. 8).
MSC-secreted VEGF and HGF reduced LPS-stimulated
HPMEC permeability by upregulating Rac1 activity in
HPMECs
To explore the mechanism by which MSC-secreted
VEGF and HGF improve HPMEC permeability, we
further investigated the effects of MSC and VEGF/HGF
on C3 transferase- and NSC23766-inhibited endothelial
paracellular and transcellular permeability. Our research
showed that the effect of MSCs on reducing endothelial
paracellular and transcellular permeability was weak-
ened when HPMECs were pretreated with the Rac1
inhibitor NSC23766. Similarly, the roles of VEGF and
HGF in improving endothelial permeability were signifi-
cantly inhibited by NSC23766 pretreatment (p < 0.05 and
p < 0.01, respectively; Fig. 9). Our research indicated
that MSC-secreted VEGF and HGF reduced injured
HPMEC permeability by upregulating Rac1 activity in
HPMECs.
VEGF/HGF and MSC treatments enhanced VE-cadherin
and occludin protein expression and reduced caveolin-1
protein expression in LPS-stimulated HPMECs via the
RhoA/Rac1 pathway
To determine the detailed mechanism by which MSC and
VEGF/HGF treatments use the RhoA/Rac1 pathway to
regulate endothelial permeability in injured HPMECs, we
examined endothelial VE-cadherin, occludin and caveolin-1
protein expression in HPMECs pretreated with RhoA
and Rac1 inhibitors. The results showed that the effects
of MSCs and VEGF/HGF on enhancing VE-cadherin
and occludin protein expression were weakened when
injured HPMECs were pretreated with the Rac1 inhibitor
NSC23766 (p < 0.05 and p < 0.01, respectively; Fig. 10).
However, caveolin-1 protein expression increased in
HPMECs pretreated with the Rac1 inhibitor NSC23766
or with the RhoA inhibitor C3 transferase (p < 0.05 and
p < 0.01, respectively; Fig. 10). Our research suggested
Fig. 5 MSC-secreted HGF restored endothelial F-actin remodelling. LPS cause “actin stress fibre” formation in HPMEC, which is the movement of actin from
the cortical rim to a disorganized intracellular fashion. It is this stress fibre formation which causes the cells to contract, increasing paracellular permeability.
After 24 h of MSC-CM and HPMEC co-culture, actin stress fibre was partially restored. However, neutralising HGF from the MSC-CM with anti-HGF antibody
caused actin stress fibre formation again. Adding MSC-CM in all groups except control group and LPS group. CM Conditioned medium, HGF Hepatocyte
growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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that VEGF/HGF and MSCs enhanced VE-cadherin and
occludin protein expression and reduced caveolin-1
protein expression in HPMECs via the RhoA/Rac1
pathway.
Discussion
ALI is characterised by increased lung permeability, pul-
monary oedema and diffuse inflammation, and is involved
in alveolar–capillary membrane disruption [13]. MSCs
Fig. 6 MSC-secreted VEGF and HGF decreased HPMEC apoptosis and improved cell viability. a, b LPS induced early apoptosis of HPMECs. MSC-CM
treatment significantly reduced the number of early apoptotic cells. However, the effect of MSCs was significantly blocked by neutralising HGF or VEGF
from the MSC-CM with anti-HGF or anti-VEGF antibody, respectively. c MTT assay confirmed that MSC-CM treatment restored cell viability to a greater
extent than LPS stimulation only. Additionally, the effect of MSC-CM treatment was significantly inhibited by neutralising VEGF from the MSC-CM with
anti-VEGF antibody. Adding MSC-CM in all groups except control group and LPS group. n = 3, *p < 0.05, **p < 0.01 vs. control group; #p < 0.05
vs. LPS group; &p < 0.05; &&p < 0.01 vs. MSC-CM group. CM Conditioned medium, FITC Fluorescein isothiocyanate, HGF Hepatocyte growth factor,
LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
Yang et al. Stem Cell Research & Therapy  (2015) 6:250 Page 8 of 14
appear to restore endothelial function via a paracrine
effect [14]. However, the detailed mechanism by which
MSCs improve endothelial permeability remains unclear
[15]. In the present study, we found that MSC-secreted
HGF protects endothelial barrier function. However,
MSC-secreted VEGF synergises with HGF in stabilising
EC barrier function. MSC-secreted HGF and VEGF
provide the same effects on lessening endothelial para-
cellular permeability and reducing transcellular permeabil-
ity. MSC-secreted HGF and VEGF synergistically restore
endothelial intercellular AJ remodelling, decrease caveolin-
1 protein expression and endothelial apoptosis, and induce
EC proliferation. Furthermore, Rac1 is the common
pathway by which VEGF and HGF regulate the paracellular
and transcellular permeability of ECs.
Endothelial injury results in barrier dysfunction, which
contributes to pulmonary oedema in ALI [16]. Two
pathways regulate permeability across the endothelial
barrier, the paracellular pathway and the transcellular
pathway [17, 18]. The primary function of the paracellu-
lar pathway is to transport small molecular substances;
however, the transcellular pathway is defined as vesicle-
mediated transport of macromolecules across the endo-
thelial barrier in a caveolae-dependent manner [19]. In
this study, we used an LPS-induced EC permeability
injury model. The results showed that the paracellular
Fig. 7 MSC-secreted VEGF and HGF upregulated Rac1 activity (Fig. 7a and b) and downregulated RhoA activity (Fig.7a and c) in LPS-stimulated
HPMECs. MSC-CM treatment upregulated Rac1 activity and downregulated RhoA activity in LPS-stimulated HPMECs. However, the effect of MSCs
was significantly inhibited by neutralising HGF or both VEGF and HGF from the MSC-CM with HGF antibody or both VEGF and HGF antibodies.
Neutralising VEGF from the MSC-CM with anti-VEGF did not affect the effect of MSCs. Adding MSC-CM in all groups except control group and
LPS group. n = 3, *p < 0.05; **p < 0.01 vs. control group; #p < 0.05 vs. LPS group; &p < 0.05; &&p < 0.01 vs. MSC-CM group. CM Conditioned medium,
HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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Fig. 8 RhoA and Rac1 activities in LPS-stimulated HPMECs were restrained by the RhoA and Rac1 inhibitors, respectively. The results showed that
C3 transferase significantly inhibited RhoA activity (Fig. 8a and b) and that NSC23766 inhibited Rac1 activity (Fig. 8a and c) in injured HPMECs
treated with MSCs or VEGF/HGF. n = 3, *p < 0.05; **p < 0.01 vs. MSC group; #p < 0.05 vs. LPS group; &p < 0.05; &&p < 0.01 vs. VEGF/HGF group.
CM Conditioned medium, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial
growth factor
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and transcellular permeability significantly increased
at 6 h following LPS stimulation, which is consistent
with the results of a previous study [20]. Therefore,
reducing transcellular and paracellular permeability
must be reduced to maintain endothelial barrier func-
tion in ALI.
MSCs potently stabilise endothelium injury by inhibit-
ing endothelial permeability [18, 21]. A strong paracrine
capacity has been proposed as the primary mechanism
of this function [22]. MSCs are capable of secreting a
few factors under normal conditions. To enhance the
therapeutic effect of MSCs, some studies have attempted
to maximise the paracrine potential of MSCs [23]. For
instance, hypoxic preconditioning of MSCs facilitated
the release of additional factors [24]. In our study, we
designed a hypoxic cell culture model to augment the
paracrine potential of MSCs. To investigate the para-
crine effect of MSCs on endothelial permeability further,
we studied the permeability of HPMECs by co-culture
with MSC-CM.
MSC-secreted HGF and VEGF are two important fac-
tors associated with endothelial permeability [8, 25, 26].
We found that MSC-secreted HGF significantly de-
creased endothelial paracellular permeability. Although
MSC-secreted VEGF alone did not reduce endothelial
paracellular permeability, MSC-secreted VEGF syner-
gises with HGF in contrast to the role of recombinant
VEGF [26]. Additionally, MSC-secreted VEGF has simi-
lar effects to HGF on increasing occluding protein
expression in ECs. The possible explanation is that dif-
ferent quantities and proportions of HGF and VEGF
exhibit different effects on endothelial permeability.
MSCs secrete VEGF and HGF in proper quantities and
proportions, thus playing additive roles in reducing the
paracellular permeability of ECs.
The transcellular pathway is defined as the vesicle-
mediated transport of macromolecules across the endo-
thelial barrier in a caveolae-dependent manner [27].
Our study showed that LPS increased transcellular
endothelial permeability. Similar to a previous study
[10], MSC-secreted VEGF reduced the LPS-induced
transcellular permeability of ECs. Furthermore, our
data indicated that MSC-secreted VEGF synergises with
MSC-secreted HGF to reduce the transcellular perme-
ability of ECs. Caveolin-1 regulates the endothelial
transcellular transport of macromolecules [28, 29]. The
results of this study showed that MSC-secreted HGF
and VEGF have an additive effect on reducing caveolin-
1 protein expression, which is one of the possible
mechanisms by which VEGF and HGF reduce the
transcellular permeability of ECs.
An increase in LPS-induced endothelial paracellular
permeability is regulated by Rho GTPases. The Rho
GTPase Rac1 is required for the maintenance of inter-
cellular adherens and tight junctions, contributing to
reducing endothelial paracellular permeability [11, 30];
however, the Rho GTPase RhoA leads to the breakage
of intercellular adherens and tight junctions, leading to
high paracellular endothelial permeability [31, 32]. Our
data showed that MSC-secreted VEGF and HGF
reduced paracellular and transcellular endothelial
permeability by upregulating Rac1 activity in ECs. The
Fig. 9 MSC-secreted VEGF and HGF reduced LPS-stimulated HPMEC permeability by upregulating Rac1 activity in HPMECs. Our research showed
that the effect of MSCs on reducing endothelial a paracellular and b transcellular permeability was weakened when injuried HPMECs were pre-
treated with the Rac1 inhibitor NSC23766. Similarly, the roles of VEGF and HGF in improving endothelial permeability were significantly inhibited
by NSC23766 pretreatment. n = 3, *p < 0.05, *p < 0.01 vs. MSC group; #p < 0.05 vs. LPS group and vs. VEGF/HGF group. CM Conditioned medium,
EC Endothelial cell, HGF Hepatocyte growth factor, LPS Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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results of our study suggested that Rac1 is the com-
mon pathway by which VEGF and HGF regulate the
paracellular and transcellular permeability of ECs.
One limitation of our study should be noted. Our study
suggested that MSC-secreted VEGF and HGF have an addi-
tive role in stabilising EC barrier function and that Rac1 is
the common pathway by which MSC-secreted VEGF and
HGF regulate the permeability of ECs. However, the mech-
anism by which MSCs secreted VEGF and HGF is not
clearly defined in this study. Our future study will employ
further research to verify the detailed mechanism of the
additive role between MSC-secreted VEGF and HGF.
Fig. 10 VEGF/HGF and MSC treatments enhanced VE-cadherin and occludin protein expression and reduced caveolin-1 protein expression in
LPS-stimulated HPMECs via the RhoA/Rac1 pathway. The results showed that the effects of MSCs and VEGF/HGF on enhancing VE-cadherin (Fig.
10a and b) and occludin protein expression (Fig. 10a and c) were weakened when injured HPMECs were pretreated with the Rac1 inhibitor NSC23766.
However, caveolin-1 protein expression (Fig. 10a and d) increased in HPMECs pretreated with the Rac1 inhibitor NSC23766 or with the RhoA inhibitor
C3 transferase. n = 3, *p< 0.05; **p< 0.01 vs. MSC group; #p< 0.05 vs. VEGF/HGF group. CM Conditioned medium, HGF Hepatocyte growth factor, LPS
Lipopolysaccharide, MSC Mesenchymal stem cell, VEGF Vascular endothelial growth factor
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Conclusion
In summary, we demonstrated that MSC-secreted HGF
protects endothelial barrier function and that MSC-
secreted VEGF may synergize with MSC-secreted HGF
to stabilise EC barrier function. MSC-secreted HGF and
VEGF may provide synergistic effects that lessen endo-
thelial paracellular permeability and that reduce trans-
cellular permeability. MSC-secreted HGF and VEGF
may synergistically restore endothelial intercellular AJ
remodelling, decrease caveolin-1 protein expression and
endothelial apoptosis, and induce EC proliferation. Fur-
thermore, Rac1 is the common pathway by which VEGF
and HGF regulate the paracellular and transcellular per-
meability of ECs.
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